Champault G
Cancer Drug Deliv. 1986 Spring;3(2):131-7. doi: 10.1089/cdd.1986.3.131.
325 implantable catheters (PAC) were successfully used for treatment of 310 patients with neoplastic diseases in 21 French medical centers. 263 were placed in central venous sites; 43 in the hepatic artery and 11 in intra-portal sites. There was no failure at insertion time nor was there any death attributable to the method. While average duration of catheterization was 182 days, 72 catheters remain patent after one year of use or longer. Occlusion risk was found to be 3.6%: 1.5% for IV sites and 13.9% for intra-arterial sites (due to smaller inner diameter). 2.4% of the implantations showed cutaneous necrosis and in 2.7% sepsis occurred. Sepsis was much more likely to occur after percutaneous insertions. These results support the use of this device for long term chemotherapy.
在法国的21家医疗中心,325根植入式导管(肺动脉导管)成功用于治疗310例肿瘤疾病患者。263根置于中心静脉部位;43根置于肝动脉,11根置于门静脉内。插入时无失败情况,也没有因该方法导致的死亡。虽然平均置管时间为182天,但72根导管在使用一年或更长时间后仍保持通畅。发现闭塞风险为3.6%:静脉部位为1.5%,动脉内部位为13.9%(由于内径较小)。2.4%的植入出现皮肤坏死,2.7%发生败血症。经皮插入后败血症更易发生。这些结果支持使用该装置进行长期化疗。